News & Media

A Malaysian success story with global aspirations

Duopharma Biotech Records New Milestone in Halal-Certified Treatments

Duopharma Biotech Berhad achieved another milestone in Halal pharmaceuticals recently, when it received Halal Certification from the Department of Islamic Development Malaysia (JAKIM) for a biosimilar product used in the treatment of anaemia associated with chronic renal failure in adult haemodialysis and predialysis patients and paediatric patients on haemodialysis.

Duopharma Biotech Maintains Focus on Domestic Market Leadership and International Growth

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

Duopharma Biotech Records 36.2% Revenue Growth and 67.8% Profit Improvement in Q1 FY2025

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

Duopharma Biotech Achieves Record Revenue With 15.5% Growth in 2024

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

Duopharma Biotech and Universiti Kebangsaan Malaysia Partner to Elevate Halal Standards in Healthcare

MoUs with Centre for Affordable Diagnostics & Therapeutics Limited and PAMOJA Therapeutics BV seek to repurpose anti-malarial drug artesunate for cancer therapy and other applications

Duopharma Biotech records strong growth in Q3 FY2024

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

Duopharma Biotech Records Robust Financial Performance in Q2 2024

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

Duopharma Biotech Returns to Support Balanced Nutrition and Promote Healthy Breakfasts Among Schoolchildren

Duopharma Biotech Berhad is supporting efforts to promote better nutrition among schoolchildren for the second year running. Through the CHAMPS® Nutribar range, the Company’s leading nutrition brand CHAMPS® is the main sponsor of the nationwide Kempen Pemakanan Seimbang CHAMPS® targeted at primary school students.

Duopharma Biotech Pursues Collaboration Opportunities in Qatar Outreach

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

Duopharma Biotech Pursues Growth Strategy Focusing on New Markets and Innovative Offerings

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

Duopharma Biotech brings Flavettes Glow to Indonesia

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

Duopharma Biotech optimistic on 2024 outlook with Q1FY2024 results

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

Duopharma Biotech forms R&D partnerships for new therapies

MoUs with Centre for Affordable Diagnostics & Therapeutics Limited and PAMOJA Therapeutics BV seek to repurpose anti-malarial drug artesunate for cancer therapy and other applications

Duopharma Biotech partners Owen Mumford to distribute medical devices

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

Duopharma Biotech ends FY2023 with a marginal increase in revenue

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.